DEVELOPMENT OF ALOPECIA DURING TREATMENT WITH A TUMOR NECROSIS FACTOR-ALPHA INHIBITOR IN A FEMALE PATIENT WITH PSORIATIC ARTHRITS: A CLINICAL CASE

Objective: to describe a case of the total development of alopecia in a female patient with psoriatic arthritis during treatment with a tumor necrosis factor-αlpha (TNF-α) inhibitor.
Materials and methods. Patient I., aged 36 years has been followed up at the Kazan’ Center of Rheumatic Diseases and Osteoporosis since 1998. At approximately the same time, the patient noted the appearance of skin eruptions behind the ears, on the skin of the scalp. She was examined by a dermatologist who diagnosed psoriasis. In 2005, she was admitted to Kazan’ Rheumatology Center, City Clinical Hospital Seven, for the development of obvious synovitis of the knee joint and for the inefficiency of therapy with nonsteroidal anti-inflammatory drugs and diagnosed with psoriatic arthritis. During the prescribed therapy with methotrexate 10 mg/week, evident menstrual irregularities were observed in the patient who stopped using the drug herself. The second pregnancy occurred in 2008. Articular syndrome progression and eruptive psoriasis were recorded in the lactation period. After lactation cessation in 2009, she was hospitalized again. Her examination revealed high laboratory activity (erythrocyte sedimentation rate, as high as 40 mm/hr); magnetic resonance imaging of the knee joints showed the signs of bilateral synovitis; lumbar spine radiography exhibited grade II sacroiliitis. Leflunomide 20 mg/day was recommended as a basic drug. In 2012, the patient used leflunomide, her condition worsened; joint pain progressed; new joints were involved into the process, and cutaneous manifestations were aggravated. To verify a diagnosis and to choose therapy, the patient was referred to a consultation at the Moscow Research Institute of Rheumatology.
Results. In connection with the high activity of the disease and with no response to the performed therapy, it was recommended to initiate therapy with biologics, such as infliximab, the drug of choice. Seven infliximab injections were well tolerated: the patient reported lower intensity of joint pains and regression of the skin manifestations of psoriasis. In 2013, after the eighth infliximab injection the patient sought medical advice because of complaints about an obvious exacerbation of psoriasis affecting the trunk, upper and lower extremities, and the development of total alopecia within a week. Discontinuation of cytostatics and biologics was recommended; whether ustekinumab therapy should be used was considered.
Conclusion. Practical interest in this clinical case is due to the development of a rare (3.3 %) adverse event in the patient with psoriatic arthritis – hair loss (total development of alopecia) during treatment with a TNF-α inhibitor. 

1. Gladman D.D. Natural history of psoriatic arthritis. Baillieres Clin Rheumatol 1994;8(2):379–94.

2. Gladman D.D., Farewell V.T., Wong K., Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6):1103–10.

3. McHugh N.J., Balachrishnan C., Jones S.M. Progression of peripheral joint disease in PsA: a 5 year prospective study. Rheumatology (Oxford) 2003;42(6):778–83.

4. Stafford L., Kane D., Murphy E. et al. Psoriasis predicts a poor short-term outcome in patients with spondyloarthropathy. Arthritis Rheum 2001;45(6):485–93.

5. Lew W., Bowcock A.M., Krueger J.G. Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. Trends Immunol 2004;25(6):295–305.

6. Griffiths C.E., Voorhees J.J. Psoriasis, T cells and autoimmunity. J R Soc Med 1996;89(6):315–9.

7. Cella M., Jarrossay D., Facchetti F. et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5(8):919–23.

8. Blanco P., Palucka А.К., Gill М. et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294(5546):1540–3.

9. Nestle F.O., Conrad C., Tun-Kyi A. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202(1):135–43.

10. de Gannes G.C., Ghoreishi M., Pope J. et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143(2):223–31.

11. Eriksen K.W., Lovato P., Skov L. et al. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005;125(5): 936–44.

12. Nestle F.O., Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 2005;125(5):xiv–xv.

13. Муравьев Ю.В., Дорошкевич И.А. Что делать, если в период лечения ингибиторами фактора некроза опухоли α возник псориаз? Научно-практическая ревматология 2011; (5):89–91. [Murav’yov Yu.V., Doroshkevich I.A. What to do, if psoriasis occurs during the period of treatment by inhibitors of tumor necrosis factor α? Nauchno-prakiticheskaya revmatologiya = Research and Practical Rheumatology 2011;(5):89–91. (In Russ.)].

14. Коротаева Т.В., Насонов Е.Л. Стандарты терапии псориатического артрита. Научнопрактическая ревматология 2009;(3):29–37. [Korotaeva T.V., Nasonov E.L. Standards of therapy of psoriatic arthritis. Nauchnoprakiticheskaya revmatologiya = Research and Practical Rheumatology 2009;(3):29–37. (In Russ.)].

15. Логинова Е.Ю., Коротаева Т.В., Климова Н.В. и др. Первый отечественный опыт применения адалимумаба при псориатическом артрите. Научно-практическая ревматология 2010;(3):83–7. [Loginova E.Yu., Korotaeva T.V., Klimova N.V. et al. First national experience of adalimumab administration at psoriatic arthritis. Nauchno-prakticheskaya revmatologiya = Research and Practical Rheumatology 2010;(3):83–7. (In Russ.)].

16. Costa L., Atteno M., Caso F. et al. Alopecia areata in a patient with psoriatic arthritis and Crohn’s disease receiving etanercept. Int J of Rheum Dis 2014;17(2):219–20.

17. Navarro R., Dauden E., Gallo E. et al. Alopecia areata during treatment of psoriasis with adalimumab and leflunomide: a case and review of the literature. Skin Pharmacol Physiol 2012;25(2):107–10.

18. Ormaechea-Pérez N., López-Pestaña A., Muñagorri-Santos A.I. et al. Alopecia areata in a patient receiving infliximab. Indian J Dermatol Venereol Leprol 2013;79(4): 529–31

19. Ribeiro L.B., Rego J.C., Estrada B.D. et al. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol 2015;90(2):232–5.

20. Lindsey S.F., Tosti A. Hair loss induced by tumor necrosis factor alpha inhibitors. J Clin Investigat Dermatol 2013;(1):6.

21. 21. Ferran M., Calvet J., Almirall M. et al. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents. J Eur Acad Dermatol Venereol 2011;25(4):479–84.

22. Neila J., Carrizosa A., Ceballos C., Camacho F.M. Alopecia areata after biologic therapy: report of a case related to adalimumab (in Spanish). Actas Dermosifiliogr 2011;102(10):827–8.